Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
156 results about "HDL cholesterol ester" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Cholesteryl ester, a dietary lipid, is an ester of cholesterol. The ester bond is formed between the carboxylate group of a fatty acid and the hydroxyl group of cholesterol. Cholesteryl esters have a lower solubility in water due to their increased hydrophobicity.
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Owner:PFIZER INC
4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Owner:PFIZER INC
Trisubstituted amine compound
InactiveUS20090023729A1Strong inhibitory activityUseful in treatmentBiocideNervous disorderDyslipidemiaCholesterylester transfer protein
The present invention relates to a compound of the general formula (1):wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted heterocyclic group, and the like; R1 is an optionally substituted alkyl group, wherein the alkyl group further may optionally be substituted by an optionally substituted homocyclic group, and the like; and R2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and / or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.
Owner:MITSUBISHI TANABE PHARMA CORP
Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Owner:PFIZER INC
Emulsion formulations for hydrophilic active agents
Owner:PITTSBURGH UNIV OF
4-amino substituted-2-substituted-1,2,3,4-tetrahydroquinolines
Owner:PFIZER INC
Annulated 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Owner:PFIZER INC
4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
Owner:PFIZER INC
Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Owner:PFIZER INC
Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
InactiveUS20020103225A1Improve aqueous concentrationImprove solubilityAntibacterial agentsPowder deliveryCholesterylester transfer proteinBiochemistry
A pharmaceutical composition comprises a solid amorphous dispersion of a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer.
Owner:BEND RES
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
InactiveUS8703204B2Organic active ingredientsPowder deliveryCrystallographyCholesterylester transfer protein
Owner:BEND RES
4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
Cholesteryl ester transfer protein inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and / or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases in some mammals, including humans.
Owner:PFIZER INC
Cholesteryl Ester Transfer Protein Inhibitors
Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compounds of Formula (I), A1 is a cyclic group, and B is a cyclic group which is attached to the heterocyclic ring directly or through a methylene group.
Owner:MERCK SHARP & DOHME LLC
Implant having a coating containing cholesterol or cholesterol ester
InactiveUS20070299512A1Improve ductilityEasy to processSurgeryCoatingsCholesteryl esterHDL cholesterol ester
A coated implant and a method of use of cholesterol or a cholesterol ester. The implant has a coating which contains one or more components selected from the group of cholesterol and cholesterol esters.
Owner:BIOTRONIK VI PATENT
Trisubstituted amine compound
InactiveUS20090029994A1Strong inhibitory activityUseful in treatmentBiocideNervous disorderDyslipidemiaCholesterylester transfer protein
The present invention relates to a compound of the general formula (1):wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted phenyl group, and the like; R1 is an optionally substituted alkyl group, and the like; and R2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and / or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.
Owner:MITSUBISHI TANABE PHARMA CORP
Compounds and methods to increase plasma HDL cholesterol levels and improve HDL functionality
InactiveUS6881860B2Improve the level ofIncreases selective uptakeBiocideCompound screeningHalf-lifeHDL particle
It has been discovered that certain selected ethers of probucol, and their pharmaceutically acceptable salts or prodrugs, are useful for increasing circulating HDL cholesterol. These compounds may also improve HDL functionality by (a) increasing clearance of cholesteryl esters, (b) increasing HDL-particle affinity for hepatic cell surface receptors or (c) increasing the half life of apoAI-HDL.
Owner:SALUTRIA PHARMACEUTICALS LLC
Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
InactiveUS20040132771A1Overcomes drawbackImprove concentrationPowder deliveryBiocideHMG-CoA reductaseBioavailability
A composition comprises (1) a solid amorphous adsorbate comprising a cholesteryl ester transfer protein (CETP) inhibitor and a substrate; and (2) an HMG-CoA reductase inhibitor. The solid amorphous adsorbate provides concentration enhancement of the CETP inhibitor relative to a control composition consisting essentially of the unadsorbed CETP inhibitor alone, resulting in improved bioavailability.
Owner:BEND RES
Compounds and methods for regulating triglyceride levels
InactiveUS20060148763A1Treating and preventing hypertriglyceridemiaBiocideOrganic chemistryLipid formationHMG-CoA reductase
The present invention provides a method of administering vitamin B6 related compounds for treatment of hypertriglyceridemia. Vitamin B6 related compounds include pyridoxal, pyridoxal-5′-phosphate, pyridoxamine, a 3-acylated analogue of pyridoxal, a 3-acylated analogue of pyridoxal-4,5-aminal, and mixtures thereof. Embodiments of the present invention also comprise co-administering a lipid lowering agent, such as a nicotinic acid, a fibrate, a HMG CoA reductase inhibitor, a cholesteryl ester transfer protein inhibitor, and combinations thereof.
Owner:MEDICURE INT INC
Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
A class of substituted pyridines that are useful for inhibiting the activity of cholesteryl ester transfer protein, and have the structural formula (IA), wherein R2, R3, R4, R5, and R6 are defined in the claims.
Owner:PHARMACIA CORP
Cosmetic material containing triple- encapsulated retinol
InactiveUS6908625B2Effective and stableStabilizing first-stabilized retinolCosmetic preparationsBiocideVitamin A RetinolSurface-active agents
The present invention concerns stabilized cosmetic material containing triple-encapsulated retinol. Unstable, fat-soluble retinol is stabilized firstly by addition into vesicles consisting of nonionic surface-active agent, cholesterol and cholesteryl ester. The firstly stabilized retinol(vesicle) is subsequently inserted into sphingosomes (a kind of multi lamellar liposome) consisting of lecithin and ceramide. Finally the double-encapsulated retinol (sphingosome) is inserted into lamellar liquid-crystal emulsifying base, thereby being triply encapsulated.
Owner:COREANA COSMETICS
Systems and apparatus for indicating risk of coronary stenosis
ActiveUS20140134654A1Increased riskHealth-index calculationMicrobiological testing/measurementAge and genderMass Spectrometry-Mass Spectrometry
A computer-based method for determining a prediction of risk and / or an indication of extent of coronary stenosis in a human subject, comprises the steps of: (a) inputting the level of at least one cholesteryl ester measured in a blood sample collected from said subject; and then (b) inputting the age and gender of said subject; and then (c) generating in said computer from said cholesteryl ester level input, said age input and said gender input a prediction of risk and / or an indication of extent of coronary stenosis blood sample by mass spectrometry.
Owner:WAKE FOREST UNIV HEALTH SCI INC
Biological markers for longevity and diseases and uses thereof
InactiveUS7491543B2Raise the possibilityLikelihood of longevityMicrobiological testing/measurementPeptide preparation methodsInsulin-like growth factorCholesterylester transfer protein
This invention provides methods of using of the sizes and levels of high-density lipoprotein (HDL) and low-density lipoprotein (LDL) particles, the -641 allele of the promoter of the gene encoding apolipoprotein C-3 (APOC-3), the 405 allele of the gene encoding cholesteryl ester transfer protein (CETP), and plasma levels of insulin-like growth factor-1 (IGF-1), adiponectin, CETP and APOC-3, for determining and increasing an individual's likelihood of longevity and of retaining cognitive function during aging, and for determining and decreasing an individual's likelihood of developing a cardiovascular-, metabolic- or age-related disease.
Owner:ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIV
Tetrahydronaphthyridine derivatives and a process for preparing the same
InactiveUS20070032485A1Reduce usageUseful in treatmentBiocideOrganic chemistryCholesterylester transfer proteinHydrogen
A novel compound of the formula (I): wherein R1 is alkoxycarbonyl or the like, R2 is alkyl or the like; R3 is hydrogen or the like; R4 is alkylene or the like; R5 is optionally substituted heterocyclic group; R6, R7, and R8 are independently hydrogen; alky, alkoxy, or the like; R10 is optionally substituted aromatic ring, or the like; or a pharmaceutically acceptable salt thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP).
Owner:MITSUBISHI TANABE PHARMA CORP
One-step assay for high-density lipoprotein cholesterol
InactiveUS20050037504A1Microbiological testing/measurementBiological testingHigh densityCholesterol Esterase
Disclosed is a method for quantifying cholesterol in high-density lipoproteins in a single step assay using a dry slide. The method for quantifying cholesterol in high-density lipoprotein comprises a first step of adding a sample onto a multi-layered dry slide wherein at least one of the layers contains phosphotungstic acid and another contains a high-density lipoprotein selective surfactant. The phosphotungstic acid precipitates non-high-density lipoproteins while the high-density lipoprotein selective surfactant only solubilizes high-density lipoproteins and does not solubilize non-HDL precipitated complexes. The cholesterol esterase then reacts with the solubilized HDL cholesterol esters to form cholesterol. Finally the cholesterol in the high-density lipoprotein is detected and quantified.
Owner:ORTHO-CLINICAL DIAGNOSTICS
Preparation method of degreased roe protein powder
ActiveCN104432106AGreat tasteEasy to eatProtein composition from fishFood preparationOrganic solventPhospholipase A2
The invention provides a preparation method of degreased roe protein powder. A degreased roe protein powder product is prepared by the following steps: carrying out mixed enzymolysis on phospholipase A1, phospholipase A2 and papain; degreasing by supercritical co2 extraction; and preparing. The method can be used for fully removing glyceride, free fatty acids, phospholipase and cholesteryl ester in roes under the condition of not using an organic solvent so as to obtain the degreased roe protein powder product which is good in taste, convenient to eat and high in additional value.
Owner:威海博宇食品有限公司
Dosage Forms Providing Controlled and Immediate Release of Cholesteryl Ester Transfer Protein Inhibitors and Immediate Release of Hmg-Coa Reductase Inhibitors
A dosage form that includes a cholesteryl ester transfer protein inhibitor in a solubility-improved form and an HMG-CoA reductase inhibitor, wherein the dosage form provides immediate release of the HMG-CoA reductase inhibitor and controlled release and immediate release of the cholesteryl ester transfer protein inhibitor.
Owner:BERCHIELLI ALFRED +3
Biomarker F7 for diagnosing white matter lesion and application thereof
The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is ceramide (d18: 0 / 24: 1 (15Z)) (Cer (d18: 0 / 24: 1 (15Z))). According to the present invention, the biomarker ceramide (d18: 0 / 24: 1 (15Z)) is combined with cholesterol-alpha-D-glucoside (Cholesteryl-alpha-D-glucoside), and is combined with 6Z, 9Z, 20-eicosatrienoic acid (6Z, 9Z, 20-Henecosatriene), ephedrine A (Cannflavanin A), cucurbitacine E (Cucurbitacine E) or cholesteryl ester 22: 6 (22: 6 Cholesteryl ester) so as to determine whether the white matter lesion exists or not; the biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Biomarker for diagnosing white matter lesion and application thereof
The invention provides a biomarker for diagnosing white matter lesion and application thereof. The biomarker is cholesterol-alpha-D-glucoside. The biomarker cholesterol-alpha-D-glucoside is combined with 6Z,9Z,20-eicosatrienoic acid, ceramide (m18:1(4E) / 24:1(15Z)), ephedrine A, cucurbitacine E, cholesteryl ester 22:6 or ceramide (d18:0 / 24:1(15Z)) to judge whether white matter lesion exists or not. The biomarker for diagnosing the white matter lesion is used for preparing a detection reagent for diagnosing the white matter lesion, and is beneficial for diagnosing whether the white matter lesion tends to exist or not and preventing the white matter lesion in advance.
Owner:BAO FENG BIOTECH (BEIJING) CO LTD
Use of CETP inhibitors and optionally HMG COA reductable inhibitors and/or antihypertensive agents
The present invention relates to cholesteryl ester transfer protein (CETP) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors optionally in combination with certain therapeutic agents, such as antihypertensive agents, in the treatment of certain diseases / disorders Applications.
Owner:PFIZER PRODS ETAT DE CONNECTICUT
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com